Cited 6 times in
Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2- pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H- pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이덕철 | - |
dc.date.accessioned | 2017-09-29T06:32:05Z | - |
dc.date.available | 2017-09-29T06:32:05Z | - |
dc.date.issued | 2005 | - |
dc.identifier.issn | 0022-3573 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/149906 | - |
dc.description.abstract | The pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d)pyrimidine-7-one (DA-8159), a new erectogenic, and nitroglycerin has been evaluated in rats. Male Sprague-Dawley rats received DA-8159 (30 mgkg−1) as a single intravenous or oral dose with the simultaneous single intravenous administration of nitroglycerin (2.5 mgkg−1). After simultaneous intravenous administration, the total area under the plasma concentration-time curve from time zero to time infinity (AUCinf) of DA-8159 (746 vs 457 μg min mL−1) was found to be significantly greater than with DA-8159 alone. Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min−1 kg−1), renal clearance (CLR) (1.65 vs 5.11 mL min−1 kg−1), and nonrenal clearance (CLNR) (38.3 vs 60.2 mL min−1 kg−1) of DA-8159 were significantly slower compared with DA-8159 alone. The slower CLNR of DA-8159 could have been due to the inhibition of the metabolism of DA-8159 by nitroglycerin, since DA-8159 is metabolized via CYP3A1/2 in rats and nitroglycerin inhibits CYP3A1/2 in rats. The slower CLR of DA-8159 could have been due to the urine flow rate-dependent CLR of DA-8159 in rats. After the simultaneous intravenous administration of nitroglycerin and DA-8159, the AUCinf of nitroglycerin was significantly smaller (635 vs 960 μg min mL−1), which could have been due to the cardiac output-dependent CL of nitroglycerin. However, after the oral administration of DA-8159, the pharmacokinetic parameters of DA-8159 with and without the intravenous administration of nitroglycerin became comparable. This was not due to the decrease in nitroglycerin's gastrointestinal absorption of DA-8159, but could have been due to changes in nitroglycerin's intestinal first-pass effect of DA-8159. Human studies are required to determine the administration time of DA-8159 when nitroglycerin is concomitantly taken. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley | - |
dc.relation.isPartOf | JOURNAL OF PHARMACY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2- pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H- pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Family Medicine (가정의학교실) | - |
dc.contributor.googleauthor | Shin Jung Lee | - |
dc.contributor.googleauthor | Soo Kyung Bae | - |
dc.contributor.googleauthor | Myung Gull Lee | - |
dc.contributor.googleauthor | Jong Won Kwon | - |
dc.contributor.googleauthor | Moohi You | - |
dc.contributor.googleauthor | Duk Chul Lee | - |
dc.identifier.doi | 10.1211/jpp.57.11.0004 | - |
dc.contributor.localId | A02716 | - |
dc.relation.journalcode | J01702 | - |
dc.identifier.eissn | 2042-7158 | - |
dc.identifier.pmid | 10.1211/jpp.57.11.0004 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1211/jpp.57.11.0004/abstract | - |
dc.contributor.alternativeName | Lee, Duk Chul | - |
dc.citation.volume | 57 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1397 | - |
dc.citation.endPage | 1405 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PHARMACY AND PHARMACOLOGY, Vol.57(11) : 1397-1405, 2005 | - |
dc.date.modified | 2017-05-04 | - |
dc.identifier.rimsid | 41997 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.